PT  - JOURNAL ARTICLE
AU  - Robert N. Weinreb
AU  - Rajni Jani
TI  - A Novel Formulation of an Ophthalmic Beta-Adrenoceptor Antagonist
DP  - 1992 Mar 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - 51--53
VI  - 46
IP  - 2
4099  - http://journal.pda.org/content/46/2/51.short
4100  - http://journal.pda.org/content/46/2/51.full
SO  - PDA J Pharm Sci Technol1992 Mar 01; 46
AB  - To minimize ocular discomfort while maintaining efficacy, a delivery system for a topical cardioselective β-adrenoceptor antagonist, betaxolol was developed. Betaxolol was formulated at 0.25% concentration in a cationic exchange resin, as a suspension. A polyacrylic acid polymer was added to increase viscosity and to increase residence time in the cul-de-sac. No significant settling was observed throughout a four-week observation period. Thus, resuspension of the formulation by frequent shaking was not required for uniformity. In rabbits, the ocular bioavailability of 0.25% betaxolol suspension was equivalent to that of 0.5% betaxolol solution.